Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fecal Microbiota Transplantation to Prevent Acute GVHD After Allogeneic HCT
NCT06026371Phase 2Active, not recruiting
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Dec 2023
- Primary completion
- Aug 2026
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Fecal Microbiota Transplantation Capsule in Acute Graft-Versus-Host Disease (aGvHD) (2 arms), sponsored by Fred Hutchinson Cancer Center. Primary endpoint: Grade III-IV acute graft versus host disease at 6 months. Started Dec 2023; status: active, not recruiting.
02
Drugs
Fecal Microbiota Transplantation Capsule
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT06026371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06026371.